Biogen PT receives Investment Bank Analyst Rating Update
20 Maxwell House, Singapore, Jan. 25, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global gene therapy market is expected to...
By Senad Karaahmetovic On Friday, the United States Food and Drug Administration (FDA) officially approved Leqembi, a new drug developed by Biogen (NASDAQ:BIIB) and Japan-based...
We are looking for further downside into wave C which could take us back to the area of wave 4.
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences...
Biogen stock is getting favorable ratings after successful trial results for its latest Alzheimer's treatment Lecanemab is Biogen's latest attempt to cure the disease after its...
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
|Average||323.12 (+13.92% Upside)|
|No. of Analysts||26|